Impact Factor
2.85
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
1.94
112 total citations
h5-index
19
h5 depth signal
Cited share
71.0%
44 of 62
Total citations
112
Citation footprint
Metric signal
1.20
External metric anchor
Self-citation
0.9%
1 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
184
Saudi Arabia
92
Egypt
31
India
29
Iran
22
Citing Fields of Research
Hematology
281
Lymphomas
84
Oncology
43
Immunology
36
Auto-Inflammatory Disorders
15
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
819
Articles tracked across the journal lifetime
Indexed publication set
62
44 cited publications
Last 12 months
16
2.7 publications/month
Open access share
100.0%
16 OA publications in the last year
Leading citing country
United States
184 citing publications
Leading citing field
Hematology
281 citing publications
Latest tracked publication
22 July 2026
10 recent records available
Coverage & Indexing History
v1n1, Jan.-Mar. 2008-
v1n1, Jan.-Mar. 2008-
Research Focus & Classification
Indexed Subjects
Hematology
Issuing & Sponsoring Bodies
Contributor
Markaz al-Malik Faysal al-Awrām
Broad Categories
Hematology
Neoplasms
MeSH Descriptors
Hematologic Diseases
Stem Cell Transplantation
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.4103/hemoncstem.hemoncstem-d-26-00026
Open DOI
From Spirometry to Survival: Ambiguities in Pulmonary Metrics for Cellular Therapy Outcomes
Was not provided for this article.
02
DOI 10.4103/hemoncstem.hemoncstem-d-26-00022
Open DOI
Revisiting autologous stem cell transplantation for LBCL in the CAR T-Cell era
Was not provided for this article.
03
DOI 10.4103/hemoncstem.hemoncstem-d-26-00042
Open DOI
Comparable Inpatient Costs and Resource Utilization with TCRαβ+/CD19+-Depleted Compared with Conventional Stem Cell Transplant for Pediatric Hematologic Malignancies
T-cell receptor alpha/beta+ T-cell/CD19+ B-cell (TCRαβ+/CD19+) depletion of allografts is increasingly used as a graft manipulation strategy for allogeneic hematopoietic stem cell transplantation (HSCT) for hematologic malignancies. Whil...
04
DOI 10.4103/hemoncstem.hemoncstem-d-25-00039
Open DOI
The Two-Step Allogeneic Stem Cell Transplant Is Associated with Excellent Engraftment, Improved Survival and Low Nonrelapse Mortality in Patients with Myelofibrosis
Myelofibrosis is a chronic myeloproliferative disorder primarily affecting older adults, and allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative treatment option. However, HSCT for myelofibrosis presents s...
05
DOI 10.4103/hemoncstem.hemoncstem-d-26-00005
Open DOI
Oncostatin M deficiency: A newly recognized inherited bone marrow failure syndrome with potential predisposition to myeloid malignancy
Inherited bone marrow failure syndromes (IBMFSs) are rare, genetically heterogeneous disorders characterized by BMF with possible increased risk of myeloid malignancies. Recent advances in genomic diagnostic techniques have identified a ...
06
DOI 10.4103/hemoncstem.hemoncstem-d-26-00007
Open DOI
Menin inhibitors in acute leukemia: Advances and future directions
Background: Acute leukemias with KMT2A rearrangements (KMT2Ar) or mutant NPM1 (NPM1m) have historically poor outcomes despite intensive therapy. Menin, a scaffold protein encoded by MEN1, is a critical cofactor for the leukemic transcrip...
07
DOI 10.4103/hemoncstem.hemoncstem-d-26-00008
Open DOI
Cancer epidemiology in the Kingdom of Saudi Arabia, 2024
Background: Cancer represents a significant and evolving public health challenge in the Kingdom of Saudi Arabia, a nation undergoing rapid socioeconomic and epidemiological transitions. This study provides a comprehensive analysis of can...
08
DOI 10.4103/hemoncstem.hemoncstem-d-26-00018
Open DOI
Impact of mental health on outcomes of patients with relapsed and/or refractory diffuse large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy
Background: A diagnosis of cancer creates a stressful situation owing to the uncertainties related to the thought of possible suffering from complications associated with treatment toxicities, the fear of not responding to the prescribed...
09
DOI 10.4103/hemoncstem.hemoncstem-d-25-00052
Open DOI
Progressive transformation of germinal centers: Bridging clinical and pathological insights for diagnostic precision
Progressive Transformation of Germinal Centers (PTGC) is a rare, benign lymphoid condition that presents considerable diagnostic challenges due to its overlapping histological and immunophenotypic features with certain lymphomas, especia...
10
DOI 10.4103/hemoncstem.hemoncstem-d-25-00048
Open DOI
Hypophosphatemia as a Marker for Immune Effector Cell-Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor T Cell Recipients
Background: Hypophosphatemia is a common electrolyte abnormality in patients receiving chimeric antigen receptor T-cell (CAR-T) therapy. Its relationship with immune effector cell-associated neurotoxicity syndrome (ICANS) remains incompl...
Bibliographical & Catalog Notes
Description based on: Vol. 1, issue 1 (Jan./Mar. 2008); title from cover.
Latest issue consulted: Vol. 1, issue 1 (Jan./Mar. 2008).
Print issues ceased with v. 4 (2011)?
Vol. 1, issue 1 also dated as Jan. 2008.
Also issued online.